Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
Objective To investigate the pharmacokinetics, effectiveness, and safety of subcutaneous (SC) abatacept treatment over 24 months in patients with polyarticular-course juvenile idiopathic arthritis (JIA). Methods In this phase III, open-label, international, multicenter, single-arm study, patients wi...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 February 2018
|
| In: |
Arthritis & rheumatology
Year: 2018, Jahrgang: 70, Heft: 7, Pages: 1144-1154 |
| ISSN: | 2326-5205 |
| DOI: | 10.1002/art.40466 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1002/art.40466 Verlag: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40466 
|
| Verfasserangaben: | Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega‐Cornejo, Ingrid Louw, Alberto Berman, Inmaculada Calvo Penadés, Jordi Antón, Francisco Ávila‐Zapata, Rubén Cuttica, Gerd Horneff, Ivan Foeldvari, Vladimir Keltsev, Daniel J. Kingsbury, Diego Oscar Viola, Rik Joos, Bernard Lauwerys, Maria Eliana Paz Gastañaga, Maria Elena Rama, Carine Wouters, John Bohnsack, Johannes Breedt, Michel Fischbach, Thomas Lutz, Kirsten Minden, Tatiana Miraval, Mahmood M.T.M. Ally, Nadina Rubio‐Pérez, Elisabeth Solau Gervais, Riana van Zyl, Xiaohui Li, Marleen Nys, Robert Wong, Subhashis Banerjee, Daniel J. Lovell, Alberto Martini, and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1679041002 | ||
| 003 | DE-627 | ||
| 005 | 20230427135322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191017s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/art.40466 |2 doi | |
| 035 | |a (DE-627)1679041002 | ||
| 035 | |a (DE-599)KXP1679041002 | ||
| 035 | |a (OCoLC)1341248170 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Brunner, Hermine I. |e VerfasserIn |0 (DE-588)1197255788 |0 (DE-627)1679040642 |4 aut | |
| 245 | 1 | 0 | |a Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis |b results from a phase III open-label study |c Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega‐Cornejo, Ingrid Louw, Alberto Berman, Inmaculada Calvo Penadés, Jordi Antón, Francisco Ávila‐Zapata, Rubén Cuttica, Gerd Horneff, Ivan Foeldvari, Vladimir Keltsev, Daniel J. Kingsbury, Diego Oscar Viola, Rik Joos, Bernard Lauwerys, Maria Eliana Paz Gastañaga, Maria Elena Rama, Carine Wouters, John Bohnsack, Johannes Breedt, Michel Fischbach, Thomas Lutz, Kirsten Minden, Tatiana Miraval, Mahmood M.T.M. Ally, Nadina Rubio‐Pérez, Elisabeth Solau Gervais, Riana van Zyl, Xiaohui Li, Marleen Nys, Robert Wong, Subhashis Banerjee, Daniel J. Lovell, Alberto Martini, and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) |
| 264 | 1 | |c 26 February 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.10.2019 | ||
| 520 | |a Objective To investigate the pharmacokinetics, effectiveness, and safety of subcutaneous (SC) abatacept treatment over 24 months in patients with polyarticular-course juvenile idiopathic arthritis (JIA). Methods In this phase III, open-label, international, multicenter, single-arm study, patients with polyarticular JIA (cohort 1, ages 6–17 years and cohort 2, ages 2–5 years) in whom treatment with ≥1 disease-modifying antirheumatic drug was unsuccessful received weight-tiered SC abatacept weekly: 10 to <25 kg (50 mg), 25 to <50 kg (87.5 mg), ≥50 kg (125 mg). Patients who had met the JIA–American College of Rheumatology 30% improvement criteria (achieved a JIA-ACR 30 response) at month 4 were given the option to continue SC abatacept to month 24. The primary end point was the abatacept steady-state serum trough concentration (Cminss) in cohort 1 at month 4. Other outcome measures included JIA-ACR 30, 50, 70, 90, 100, and inactive disease status, the median Juvenile Arthritis Disease Activity Score in 71 joints using the C-reactive protein level (JADAS-71–CRP) over time, safety, and immunogenicity. Results The median abatacept Cminss at month 4 (primary end point) and at month 24 was above the target therapeutic exposure (10 μg/ml) in both cohorts. The percentage of patients who had achieved JIA-ACR 30, 50, 70, 90, or 100 responses or had inactive disease responses at month 4 (intent-to-treat population) was 83.2%, 72.8%, 52.6%, 28.3%, 14.5%, and 30.1%, respectively, in cohort 1 (n = 173) and 89.1%, 84.8%, 73.9%, 58.7%, 41.3%, and 50.0%, respectively, in cohort 2 (n = 46); the responses were maintained to month 24. The median (interquartile range) JADAS-71–CRP improved from baseline to month 4: cohort 1, from 21.0 (13.5, 30.3) to 4.6 (2.1, 9.4); cohort 2, from 18.1 (14.0, 23.1) to 2.1 (0.3, 4.4). Improvements were sustained to month 24, at which time 27 of 173 patients (cohort 1) and 11 of 22 patients (cohort 2) had achieved JADAS-71–CRP remission. No unexpected adverse events were reported; 4 of 172 patients (2.3%) in cohort 1 and 4 of 46 (8.7%) in cohort 2 developed anti-abatacept antibodies, with no clinical effects. Conclusion Weight-stratified SC abatacept yielded target therapeutic exposures across age and weight groups, was well tolerated, and improved polyarticular JIA symptoms over 24 months. | ||
| 700 | 1 | |a Lutz, Thomas |d 1970- |e VerfasserIn |0 (DE-588)142249319 |0 (DE-627)634794914 |0 (DE-576)329369474 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology |d Hoboken, NJ : Wiley, 2014 |g 70(2018), 7, Seite 1144-1154 |h Online-Ressource |w (DE-627)777780615 |w (DE-600)2754614-7 |w (DE-576)400527065 |x 2326-5205 |7 nnas |a Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label study |
| 773 | 1 | 8 | |g volume:70 |g year:2018 |g number:7 |g pages:1144-1154 |g extent:11 |a Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label study |
| 856 | 4 | 0 | |u https://doi.org/10.1002/art.40466 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40466 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191017 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 142249319 |a Lutz, Thomas |m 142249319:Lutz, Thomas |d 910000 |d 910500 |e 910000PL142249319 |e 910500PL142249319 |k 0/910000/ |k 1/910000/910500/ |p 23 | ||
| 999 | |a KXP-PPN1679041002 |e 3523425190 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 17.10.2019"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1679041002","language":["eng"],"title":[{"title_sort":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis","subtitle":"results from a phase III open-label study","title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis"}],"person":[{"given":"Hermine I.","family":"Brunner","role":"aut","roleDisplay":"VerfasserIn","display":"Brunner, Hermine I."},{"given":"Thomas","family":"Lutz","role":"aut","roleDisplay":"VerfasserIn","display":"Lutz, Thomas"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"disp":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis results from a phase III open-label studyArthritis & rheumatology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"777780615","language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American College of Rheumatology"}],"pubHistory":["66.2014 -"],"part":{"text":"70(2018), 7, Seite 1144-1154","volume":"70","extent":"11","year":"2018","issue":"7","pages":"1144-1154"},"titleAlt":[{"title":"Arthritis and rheumatology"}],"title":[{"title_sort":"Arthritis & rheumatology","subtitle":"an official journal of the American College of Rheumatology","title":"Arthritis & rheumatology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Hoboken, NJ","publisher":"Wiley","dateIssuedKey":"2014","dateIssuedDisp":"2014-"}],"id":{"eki":["777780615"],"zdb":["2754614-7"],"issn":["2326-5205"]}}],"origin":[{"dateIssuedDisp":"26 February 2018","dateIssuedKey":"2018"}],"id":{"eki":["1679041002"],"doi":["10.1002/art.40466"]},"name":{"displayForm":["Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega‐Cornejo, Ingrid Louw, Alberto Berman, Inmaculada Calvo Penadés, Jordi Antón, Francisco Ávila‐Zapata, Rubén Cuttica, Gerd Horneff, Ivan Foeldvari, Vladimir Keltsev, Daniel J. Kingsbury, Diego Oscar Viola, Rik Joos, Bernard Lauwerys, Maria Eliana Paz Gastañaga, Maria Elena Rama, Carine Wouters, John Bohnsack, Johannes Breedt, Michel Fischbach, Thomas Lutz, Kirsten Minden, Tatiana Miraval, Mahmood M.T.M. Ally, Nadina Rubio‐Pérez, Elisabeth Solau Gervais, Riana van Zyl, Xiaohui Li, Marleen Nys, Robert Wong, Subhashis Banerjee, Daniel J. Lovell, Alberto Martini, and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)"]}} | ||
| SRT | |a BRUNNERHERSUBCUTANEO2620 | ||